Digranes A, Dibb W L, Benonisen E
Acta Pathol Microbiol Immunol Scand B. 1983 Apr;91(2):141-4. doi: 10.1111/j.1699-0463.1983.tb00023.x.
The in vitro activity of the novel beta-lactam antibiotic, N-formimidoyl thienamycin (N-f thienamycin) has been compared with those of cefoxitin and tobramycin. An agar dilution method was employed. N-f thienamycin was active against all Enterobacteriaceae isolates (MIC less than or equal to 4 mg/l). All Pseudomonas aeruginosa isolates were inhibited by 2 mg/l. N-f thienamycin was also active against Acinetobacter calcoaceticus (96 per cent inhibited by 0.5 mg/l) and Gram-positive cocci. All enterococci were inhibited by 2 mg/l. The drug was active against Haemophilus influenzae (MIC less than or equal to 1 mg/l) and the Bacteroides fragilis group (MIC less than or equal to 0.5 mg/l). Cefoxitin was inactive against most Enterobacter and A. calcoaceticus isolates and all P. aeruginosa and enterococcal isolates. Tobramycin was virtually inactive against Gram-positive cocci other than Staphylococcus aureus. N-f thienamycin thus has a broad spectrum of in vitro activity, greater than that of cefoxitin and tobramycin, and may therefore be useful in the treatment of serious infection, particularly when the aetiology is unknown.
新型β-内酰胺抗生素N-甲酰亚胺硫霉素（N-f硫霉素）的体外活性已与头孢西丁和妥布霉素的活性进行了比较。采用琼脂稀释法。N-f硫霉素对所有肠杆菌科分离株均有活性（最低抑菌浓度小于或等于4mg/L）。所有铜绿假单胞菌分离株均被2mg/L的浓度所抑制。N-f硫霉素对醋酸钙不动杆菌（0.5mg/L可抑制96%）和革兰氏阳性球菌也有活性。所有肠球菌均被2mg/L的浓度所抑制。该药物对流感嗜血杆菌（最低抑菌浓度小于或等于1mg/L）和脆弱拟杆菌群（最低抑菌浓度小于或等于0.5mg/L）有活性。头孢西丁对大多数肠杆菌属和醋酸钙不动杆菌分离株以及所有铜绿假单胞菌和肠球菌分离株均无活性。妥布霉素除对金黄色葡萄球菌外，对革兰氏阳性球菌几乎无活性。因此，N-f硫霉素具有广泛的体外活性，比头孢西丁和妥布霉素的活性更强，因此可能对治疗严重感染有用，特别是在病因不明时。
